Moratalla-Navarro Ferran, Díez-Villanueva Anna, Garcia-Serrano Ainhoa, Closa Adrià, Cordero David, Solé Xavier, Guinó Elisabet, Sanz-Pamplona Rebeca, Sanjuan Xavier, Santos Cristina, Biondo Sebastiano, Salazar Ramón, Moreno Victor
Oncology Data Analytics Program, Catalan Institute of Oncology (ICO), 08908 Barcelona, Spain.
Colorectal Cancer Group, Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain.
Cancers (Basel). 2023 Jun 23;15(13):3301. doi: 10.3390/cancers15133301.
We aimed to identify and validate a set of miRNAs that could serve as a prognostic signature useful to determine the recurrence risk for patients with COAD. Small RNAs from tumors of 100 stage II, untreated, MSS colon cancer patients were sequenced for the discovery step. For this purpose, we built an miRNA score using an elastic net Cox regression model based on the disease-free survival status. Patients were grouped into high or low recurrence risk categories based on the median value of the score. We then validated these results in an independent sample of stage II microsatellite stable tumor tissues, with a hazard ratio of 3.24, (CI = 1.05-10.0) and a 10-year area under the receiver operating characteristic curve of 0.67. Functional analysis of the miRNAs present in the signature identified key pathways in cancer progression. In conclusion, the proposed signature of 12 miRNAs can contribute to improving the prediction of disease relapse in patients with stage II MSS colorectal cancer, and might be useful in deciding which patients may benefit from adjuvant chemotherapy.
我们旨在识别并验证一组可作为预后特征的微小RNA,用于确定结肠癌患者的复发风险。在发现阶段,我们对100例未经治疗的II期错配修复功能完整(MSS)结肠癌患者的肿瘤小RNA进行了测序。为此,我们基于无病生存状态,使用弹性网Cox回归模型构建了一个微小RNA评分。根据评分的中位数,将患者分为高复发风险或低复发风险类别。然后,我们在II期微卫星稳定肿瘤组织的独立样本中验证了这些结果,风险比为3.24,(置信区间=1.05-10.0),10年受试者工作特征曲线下面积为0.67。对特征中存在的微小RNA进行功能分析,确定了癌症进展中的关键途径。总之,所提出的12种微小RNA特征有助于改善II期MSS结直肠癌患者疾病复发的预测,可能有助于决定哪些患者可能从辅助化疗中获益。